Richard Mott is currently a principal in Walkabout Consulting LLC, a management consulting and private equity firm. Mr. Mott currently consults for Warburg Pincus as an Executive in Residence. Mr. Mott served as President and Chief Executive Officer and Director of Kyphon Inc., a NASDAQ-listed global medical device company focused on minimally invasive spinal therapies, through its acquisition by Medtronic, Inc. in late 2007. Prior to Kyphon, Mr. Mott held several executive positions, most recently as Chief Operating Officer at Wilson Greatbatch Technologies, Inc., a NYSE-listed medical technology company as well as executive operating roles within the Bristol-Myers Squibb Company. Mr. Mott is currently Executive Chairman of the Board of Directors of Microchips Biotech, Inc., a company based on micro reservoir technology incorporating long-term implantable drug delivery technologies; Chairman of the Board of Directors of Silk Road Medical, a company which uses surgical techniques to protect the brain from stroke risk during carotid artery stenting; Executive Chairman of the Board of Directors of Relievant Medsystems, a company using therapeutic nerve ablation for the treatment of chronic low back pain; and member of the Board of Directors of Treace Medical Concepts, a company focused on foot and ankle surgical products. Mr. Mott is a Director/Owner of VFD Technologies, a private equity firm that invests in, acquires and owns manufacturing businesses with unique technical capabilities that specialize in high performance materials.
George Whitesides, Ph.D.
Woodford L. and Ann A. Flowers University Professor, Harvard University
Dr. Whitesides joined Harvard’s Department of Chemistry in 1982 and served as department chairman from 1986 to 1989. From 1963 to 1982, he was a faculty member at Massachusetts Institute of Technology. Dr. Whitesides held advisory positions on the National Research Council, National Science Foundation and the Department of Defense’s Defense Advanced Research Projects Agency (DARPA), and he is a member of the American Academy of Arts and Sciences, National Academy of Sciences, National Academy of Engineering and the American Philosophical Society, among other organizations. He has received dozens of honors, including the American Chemical Society (ACS) Award in Pure Chemistry (1975), the Arthur C. Cope Award (1995), the DARPA Award for Significant Technical Achievement (1996), the National Medal of Science (1998), the Von Hippel Award (2000), the Kyoto Prize (2003), the Dan David Award (2005), the Welch Award (2005), the Priestley Award (2007), the American Institute of Chemists Gold Medal (2007), the Prince of Asturias Foundation Award (2008), the Nanoscience Prize (2008), the Wheland Medal (2008) and the Benjamin Franklin Medal in Chemistry (2009). In addition to Aresenal Medical, George is a co-founder of a number of companies including Genzyme, GelTex, Theravance and 480 Biomedical. He received a Bachelor of Arts from Harvard University in 1960 and a doctorate from the California Institute of Technology in 1964.
Robert Langer, D.Sc.
David H. Koch Institute Professor, Massachusetts Institute of Technology
Robert S. Langer is one of 14 Institute Professors (the highest honor awarded to a faculty member) at the Massachusetts Institute of Technology (MIT). Dr. Langer has written approximately 1,130 articles. He also has approximately 800 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed more than 250 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history. He served as a member of the U.S. FDA’s SCIENCE Board, the agency’s highest advisory board, from 1995-2002, and as its chairman from 1999-2002. Dr. Langer has received more than 200 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; and the 2008 Millennium Prize, the world’s largest technology prize. He is the only engineer to receive the Gairdner Foundation International Award; 76 recipients of this award have subsequently received a Nobel Prize. Among his multiple accolades, Forbes Magazine selected Dr. Langer as "one of the 15 innovators worldwide who will reinvent our future."
Carmichael Roberts, Ph.D.
General Partner, North Bridge Venture Partners
Carmichael Roberts joined North Bridge Venture Partners in 2007 where he focuses mainly on early-stage companies that make products using unique chemistry and materials inventions. Prior to North Bridge, Dr. Roberts co-founded and served as the president and chief executive officer of Arsenal Medical. Dr. Roberts has co-founded other ventures, including several focused on life sciences. In 1999, Dr. Roberts was named one of the world’s top 100 young entrepreneurs by MIT’s Technology Review. Prior to his entrepreneurial career, Dr. Roberts worked in business development at GelTex Pharmaceuticals, which was acquired by Genzyme for $1.3 billion, and in new product and business development at Dow Chemical (formerly Union Carbide Corporation). Dr. Roberts received his Bachelor of Science and doctorate in organic chemistry from Duke University, and he completed his postdoctoral National Science Foundation fellowship at Harvard University. Dr. Roberts also holds a master’s degree in business administration from the MIT Sloan School of Management. He serves as an advisor for MIT’s Deshpande Center for Technological Innovation, Harvard’s Nanoscale Science and Engineering Center and the schools of Science and Engineering at Duke University.
Maria Palasis, Ph.D.
President and Chief Executive Officer of Arsenal Medical
Maria Palasis is Chief Executive Officer of Arsenal Medical. Prior to joining Arsenal Medical, Dr. Palasis was R&D director at Boston Scientific, where she managed a portfolio of external biotech and medical device investments and was responsible for the development of new convergence products. Dr. Palasis was as an early member of the team that created the TAXUS® drug-eluting stent, the single most important revenue generator for Boston Scientific at $3B/year. She held a number of positions within Boston Scientific that included strategic planning for the development of advanced combination therapies, managing alliances through clinical trials, and building and directing the company’s centralized infrastructure for the biological testing of drug eluting stent technologies. Maria received her Bachelor of Science and doctorate in chemical engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.
Polaris Venture Partners
Paulina Hill is a Principal at Polaris Partners. Paulina joined Polaris in 2011 and focuses on investments in healthcare.
Paulina serves on the boards of Arsenal Medical, Faraday Pharmaceuticals and KinDex Pharmaceuticals and is an observer on the boards of MicroCHIPS and 480 Biomedical. Paulina also works closely with Arsia Therapeutics, an early-stage Bob Langer-founded startup which she was actively involved in spinning out of MIT. Paulina serves on the board of The Capital Network, a non-profit that provides fundraising education to startup entrepreneurs and is part of the Lead Mentor team for Canadian Entrepreneurs in New England.
Prior to joining Polaris, Paulina completed her postdoctoral fellowship in the Chemical Engineering department at the Massachusetts Institute of Technology. In the laboratory of Bob Langer, Paulina worked on developing novel biomaterial scaffolds and drug delivery systems for neural applications. Paulina is the founding president of the MIT Postdoctoral Association, and served on the MIT Intellectual Property Presidential Committee.
Paulina completed her PhD in Molecular Medicine with a Tissue Engineering focus at Wake Forest University School of Medicine. Her graduate school work resulted in over 40 published abstracts, awards and peer reviewed manuscripts. Her research contributed to numerous patents and the formation of the startup KeraNetics to commercialize the platform technology. Paulina graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry. She attended East Carolina on an athletic scholarship where she was captain of the women’s tennis team.
Managing Director, Essex Woodlands Health Ventures
Guido Neels served as chief operating officer of Guidant Corporation, a world leader in the development of cardiovascular medical products, from May 2004 until his retirement in November 2005. Mr. Neels was responsible for the global operations of Guidant's four operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery and Endovascular Solutions. From December 2002 to May 2004, he was group chairman, office of the president at Guidant, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. From January 2000 to December 2002, he was president of Guidant for Europe, Middle East, Africa and Canada. He previously served as vice president of global marketing for Vascular Intervention and as managing director for German and Central European operations. From 1982 to 1994, until Guidant was spun off as an independent public company from Eli Lilly and Co., Mr. Neels held various general management and sales and marketing positions at Lilly in the U.S. and Europe.
Since founding Intersouth in 1985, Dennis Dougherty has been active in all aspects of the venture investment process. He has served on dozens of boards of directors for both private and public companies. He is known for his experienced insight, consensus building and syndicate leadership.
Dennis has invested in and worked with portfolio companies through several economic cycles and has served as interim CEO when necessary. He has long been active in the venture industry having served on the board of directors of the National Venture Capital Association, on the Steering Committee for the Kauffman Fellows Program and as a mentor for two classes of Kauffman Fellows. He also served on the Board of the NC State University Seed Fund and the Governor’s Biotechnology Steering Committee. He was a founder of the highly successful Council for Entrepreneurial Development (CED) and the Chair of its first Venture Conference. In 2005, Mr. Dougherty was named the Ernst & Young Entrepreneur of the Year for the Carolinas.
Prior to founding Intersouth, Mr. Dougherty was an office managing partner and head of the high growth business practice for Touche Ross & Co. Before entering finance and accounting, he was in sales and marketing for petrochemicals and polymers. He holds a B.A. from Oklahoma City University, where he was named Distinguished Alumnus of the Year, and where he served on the Board of Trustees for 8 years.